PAVmed (NASDAQ:PAVM – Get Free Report) and Disaboom (OTCMKTS:MEDH – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.
Profitability
This table compares PAVmed and Disaboom’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PAVmed | 564.79% | -242.99% | -17.25% |
| Disaboom | 15.34% | N/A | N/A |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for PAVmed and Disaboom, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PAVmed | 1 | 1 | 1 | 0 | 2.00 |
| Disaboom | 0 | 0 | 0 | 0 | 0.00 |
Volatility & Risk
PAVmed has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Disaboom has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.
Insider & Institutional Ownership
19.9% of PAVmed shares are owned by institutional investors. 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares PAVmed and Disaboom”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PAVmed | $70,000.00 | 90.14 | $400,000.00 | ($22.77) | -0.28 |
| Disaboom | $1.76 million | 0.51 | $270,000.00 | $0.01 | 0.13 |
PAVmed has higher earnings, but lower revenue than Disaboom. PAVmed is trading at a lower price-to-earnings ratio than Disaboom, indicating that it is currently the more affordable of the two stocks.
Summary
PAVmed beats Disaboom on 8 of the 14 factors compared between the two stocks.
About PAVmed
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
About Disaboom
Dazed, Inc. focuses on retail, distribution, hospitality, licensing, and franchising of portfolio of counterculture brands. The company was formerly known as MedX Holdings, Inc. and changed its name to Dazed, Inc. in October 2022. Dazed, Inc. was founded in 2004 and is based in Cheyenne, Wyoming.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
